Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension.

Gingles CR, Symon R, Gandy SJ, Struthers AD, Houston G, MacDonald TM, Lang CC, Donnan PT, George J.

J Hypertens. 2019 Jul 1. doi: 10.1097/HJH.0000000000002189. [Epub ahead of print]

PMID:
31268872
2.

Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350.

Fortuny J, Gilsenan A, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linnér L, MacDonald TM, Plana E, Ruigómez A, Schink T, Ziemiecki R, Andrews EB.

Drug Saf. 2019 Oct;42(10):1167-1177. doi: 10.1007/s40264-019-00836-z.

3.

Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study.

Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linnér L, MacDonald TM, Odsbu I, Plana E, Ruigómez A, Schink T, Ziemiecki R, Andrews EB.

Drug Saf. 2019 Oct;42(10):1179-1190. doi: 10.1007/s40264-019-00835-0.

4.

Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.

Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R.

BMJ. 2019 Apr 10;365:l1204. doi: 10.1136/bmj.l1204.

5.

Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitations.

Rogers A, Flynn RWV, Mackenzie IS, MacDonald TM.

BMC Med Res Methodol. 2019 Jan 30;19(1):24. doi: 10.1186/s12874-019-0663-6.

6.

Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure.

Geissbühler Y, Vile J, Koren G, Guennec M, Butzkueven H, Tilson H, MacDonald TM, Hellwig K.

Ther Adv Neurol Disord. 2018 Nov 3;11:1756286418804760. doi: 10.1177/1756286418804760. eCollection 2018.

7.

The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD.

Flynn RWV, MacDonald TM, Chalmers JD, Schembri S.

Respir Res. 2018 Dec 12;19(1):249. doi: 10.1186/s12931-018-0960-3.

8.

Identifying poor adherence to antihypertensive medications in patients with resistant hypertension.

Mackenzie IS, MacDonald TM.

Br J Clin Pharmacol. 2019 Jan;85(1):5-7. doi: 10.1111/bcp.13806. Epub 2018 Nov 26. No abstract available.

9.

Reaching an ACCORD on Glycemia and Systolic Blood Pressure Targets in Type 2 Diabetes Mellitus.

MacDonald TM, Mackenzie IS.

J Am Heart Assoc. 2018 Sep 18;7(18):e010508. doi: 10.1161/JAHA.118.010508. No abstract available.

10.

The effect of indapamide vs. bendroflumethiazide for primary hypertension: a systematic review.

Macfarlane TV, Pigazzani F, Flynn RWV, MacDonald TM.

Br J Clin Pharmacol. 2019 Feb;85(2):285-303. doi: 10.1111/bcp.13787. Epub 2018 Nov 28. Review.

PMID:
30312512
11.

Ibuprofen and Paracetamol: Acceptably Safe for All?

Pigazzani F, Mackenzie I, MacDonald TM.

Drug Saf. 2018 Nov;41(11):999-1001. doi: 10.1007/s40264-018-0717-4. No abstract available.

12.
13.

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8. Epub 2018 Apr 11. Erratum in: Lancet Diabetes Endocrinol. 2018 Aug;6(8):e16.

14.

The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment.

Rorie DA, Flynn RWV, Mackenzie IS, MacDonald TM, Rogers A.

Trials. 2017 Nov 23;18(1):557. doi: 10.1186/s13063-017-2318-4.

15.

Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.

MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes G, Brown MJ; British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm‐based Therapy (PATHWAY).

J Am Heart Assoc. 2017 Nov 18;6(11). pii: e006986. doi: 10.1161/JAHA.117.006986.

16.

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.

Tornio A, Flynn R, Morant S, Velten E, Palmer CNA, MacDonald TM, Doney ASF.

Clin Pharmacol Ther. 2018 Feb;103(2):281-286. doi: 10.1002/cpt.780. Epub 2017 Sep 19.

17.

Electronic case report forms and electronic data capture within clinical trials and pharmacoepidemiology.

Rorie DA, Flynn RWV, Grieve K, Doney A, Mackenzie I, MacDonald TM, Rogers A.

Br J Clin Pharmacol. 2017 Sep;83(9):1880-1895. doi: 10.1111/bcp.13285. Epub 2017 Apr 22. Review.

18.

Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.

Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS, MacDonald TM.

Br J Clin Pharmacol. 2017 Jun;83(6):1298-1308. doi: 10.1111/bcp.13205. Epub 2017 Jan 23.

19.

Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.

Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM.

Br J Clin Pharmacol. 2017 Mar;83(3):653-663. doi: 10.1111/bcp.13152. Epub 2016 Nov 12.

20.

Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).

MacDonald TM, Hawkey CJ, Ford I, McMurray JJV, Scheiman JM, Hallas J, Findlay E, Grobbee DE, Hobbs FDR, Ralston SH, Reid DM, Walters MR, Webster J, Ruschitzka F, Ritchie LD, Perez-Gutthann S, Connolly E, Greenlaw N, Wilson A, Wei L, Mackenzie IS.

Eur Heart J. 2017 Jun 14;38(23):1843-1850. doi: 10.1093/eurheartj/ehw387. Erratum in: Eur Heart J. 2016 Dec 24;:.

21.

Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.

Mackenzie IS, Ford I, Walker A, Hawkey C, Begg A, Avery A, Taggar J, Wei L, Struthers AD, MacDonald TM; ALL-HEART study group.

BMJ Open. 2016 Sep 8;6(9):e013774. doi: 10.1136/bmjopen-2016-013774.

23.

Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study.

Rorie DA, Rogers A, Mackenzie IS, Ford I, Webb DJ, Willams B, Brown M, Poulter N, Findlay E, Saywood W, MacDonald TM.

BMJ Open. 2016 Feb 9;6(2):e010313. doi: 10.1136/bmjopen-2015-010313.

24.

Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.

Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group.

Lancet Diabetes Endocrinol. 2016 Feb;4(2):136-47. doi: 10.1016/S2213-8587(15)00377-0. Epub 2015 Oct 18.

25.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group.

Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20.

26.

Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension.

Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I, Brown MJ.

BMJ Open. 2015 Aug 7;5(8):e008951. doi: 10.1136/bmjopen-2015-008951.

27.

Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension.

Brown MJ, Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I.

BMJ Open. 2015 Aug 7;5(8):e008086. doi: 10.1136/bmjopen-2015-008086.

28.

Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial.

MacDonald TM, Williams B, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Mackenzie IS, Salsbury J, Morant S, Ford I, Brown MJ.

BMJ Open. 2015 Aug 7;5(8):e007645. doi: 10.1136/bmjopen-2015-007645.

29.

Exaggerated Exercise Blood Pressure Response and Future Cardiovascular Disease.

Tzemos N, Lim PO, Mackenzie IS, MacDonald TM.

J Clin Hypertens (Greenwich). 2015 Nov;17(11):837-44. doi: 10.1111/jch.12629. Epub 2015 Aug 3.

30.

Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?

Jennings CG, MacDonald TM, Wei L, Brown MJ, McConnachie L, Mackenzie IS.

Trials. 2015 Mar 7;16:80. doi: 10.1186/s13063-015-0582-8.

31.

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.

Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, Keskimäki I, Badrick E, Renehan AG, Buchan IE, Bowker SL, Minhas-Sandhu JK, Zafari Z, Marra C, Johnson JA, Stricker BH, Uitterlinden AG, Hofman A, Ruiter R, de Keyser CE, MacDonald TM, Wild SH, McKeigue PM, Colhoun HM; Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium.

Diabetologia. 2015 Mar;58(3):493-504. doi: 10.1007/s00125-014-3456-9. Epub 2014 Dec 7.

PMID:
25481707
32.

Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis.

Flynn RW, MacDonald TM, Hapca A, MacKenzie IS, Schembri S.

Respir Res. 2014 Nov 19;15:141. doi: 10.1186/s12931-014-0141-y.

33.

Cardiovascular risk associated with sodium-containing medicines.

Wei L, Mackenzie IS, MacDonald TM, George J.

Expert Opin Drug Saf. 2014 Nov;13(11):1515-23. doi: 10.1517/14740338.2014.970163. Epub 2014 Oct 10. Review.

PMID:
25300906
34.

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.

MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, Hallas J, Hawkey CJ, Ralston S, Walters M, Webster J, McMurray J, Perez Ruiz F, Jennings CG; Members of the FAST Study Group.

BMJ Open. 2014 Jul 10;4(7):e005354. doi: 10.1136/bmjopen-2014-005354.

35.

Renal artery stenosis-when to screen, what to stent?

Jennings CG, Houston JG, Severn A, Bell S, Mackenzie IS, Macdonald TM.

Curr Atheroscler Rep. 2014 Jun;16(6):416. doi: 10.1007/s11883-014-0416-2. Review.

36.

Up-titration of allopurinol in patients with gout.

Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, De Caterina R, Riches PL, Ralston SH, MacDonald TM; FAST study group.

Semin Arthritis Rheum. 2014 Aug;44(1):25-30. doi: 10.1016/j.semarthrit.2014.01.004. Epub 2014 Jan 23.

PMID:
24560169
37.

High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study.

Pauriah M, Elder DH, Ogston S, Noman AY, Majeed A, Wyatt JC, Choy AM, Macdonald TM, Struthers AD, Lang CC.

Heart. 2014 Jun;100(11):867-72. doi: 10.1136/heartjnl-2013-304678. Epub 2014 Feb 19.

PMID:
24553389
38.

Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial.

Witham MD, Ireland S, Houston JG, Gandy SJ, Waugh S, Macdonald TM, Mackenzie IS, Struthers AD.

Hypertension. 2014 Apr;63(4):706-12. doi: 10.1161/HYPERTENSIONAHA.113.02177. Epub 2014 Jan 13.

PMID:
24420547
39.

The authors reply.

Wei L, MacDonald TM, Murphy MJ.

Kidney Int. 2014 Jan;85(1):211. doi: 10.1038/ki.2013.386. No abstract available.

40.

Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study.

George J, Majeed W, Mackenzie IS, Macdonald TM, Wei L.

BMJ. 2013 Nov 26;347:f6954. doi: 10.1136/bmj.f6954.

41.

Effectiveness of newspaper advertising for patient recruitment into a clinical trial.

Hapca A, Jennings CG, Wei L, Wilson A, MacDonald TM, Mackenzie IS.

Br J Clin Pharmacol. 2014 Jun;77(6):1064-72. doi: 10.1111/bcp.12262.

42.

Estimated GFR reporting is associated with decreased nonsteroidal anti-inflammatory drug prescribing and increased renal function.

Wei L, MacDonald TM, Jennings C, Sheng X, Flynn RW, Murphy MJ.

Kidney Int. 2013 Jul;84(1):174-8. doi: 10.1038/ki.2013.76. Epub 2013 Mar 13.

44.

Hypertriglyceridemia and acute pancreatitis.

Murphy MJ, Sheng X, MacDonald TM, Wei L.

JAMA Intern Med. 2013 Jan 28;173(2):162-4. doi: 10.1001/2013.jamainternmed.477. No abstract available.

PMID:
23183821
45.

Appendicectomy is associated with increased pregnancy rate: a cohort study.

Wei L, Macdonald TM, Shimi SM.

Ann Surg. 2012 Dec;256(6):1039-44. doi: 10.1097/SLA.0b013e3182766250.

PMID:
23154396
46.

The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population.

Sheng X, Murphy MJ, MacDonald TM, Wei L.

BMC Public Health. 2012 Aug 30;12:712. doi: 10.1186/1471-2458-12-712.

47.

Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease.

Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD.

J Am Coll Cardiol. 2012 Sep 11;60(11):960-8. doi: 10.1016/j.jacc.2012.04.049. Epub 2012 Aug 22.

48.

Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.

Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ.

JAMA. 2012 Aug 22;308(8):804-11. doi: 10.1001/jama.2012.8439.

PMID:
22910758
49.

Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.

Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L.

BMJ. 2012 Jul 13;345:e4447. doi: 10.1136/bmj.e4447.

50.

Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.

Mackenzie IS, Wei L, Macdonald TM.

Eur J Clin Pharmacol. 2013 Feb;69(2):133-41. doi: 10.1007/s00228-012-1335-1. Epub 2012 Jun 26.

Supplemental Content

Loading ...
Support Center